Start of the POP-Durva clinical trial

10 octobre 2021

The PRISM-I trial promoted by Gustave Roussy and Prism began on October 5, 2021.

The objectives of this study are to:

i. define the effectiveness of anti-PDL1 antibodies at 6 weeks,

ii. decipher the immune response at the single cell and spatial level.

200 patients with triple negative early breast cancer will be recruited.

This study is supported by the arc foundation.

 Prism est un partenariat unique entre


Centre National de Médecine de Précision en Oncologie

Nous contacter

Prism  IHU-B

Bâtiment de médecine moléculaire

32 Rue Camille Desmoulins

94800 Villejuif

Tél. +33(0)1 42 11 00 00

info -at-



Rejoindre nos équipes

Appels à projets


Les cookies

Mentions légales

Réseaux sociaux